# Vivesto > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/vivesto). ## Overview Vivesto AB is a Swedish drug development company based in Stockholm that develops oncology programs for both human and veterinary use. Its portfolio centers on Cantrixil for blood cancer and Paccal Vet, a micellar paclitaxel program being studied in dogs and cats with cancer. ## Products & services • Cantrixil for hematologic cancers • Paccal Vet (micellar paclitaxel) for veterinary oncology • Clinical development of oncology drug candidates • Partnering and out-licensing of development-stage assets - **Human oncology programs** (50%) — Development-stage cancer therapies for difficult-to-treat human malignancies. - **Veterinary oncology programs** (50%) — Cancer treatments and studies for dogs and cats with solid tumors and HSA. - Cantrixil for hematologic cancers - Paccal Vet (micellar paclitaxel) for veterinary oncology - Clinical development of oncology drug candidates - Partnering and out-licensing of development-stage assets ## Customers Vivesto does not sell to mass-market end customers; its commercial counterparties are primarily pharmaceutical and biotech partners, clinical investigators, and veterinary oncology stakeholders. In practice, the company’s programs are designed to create value for future licensing partners that can fund late-stage development and commercialization, while clinical sites and study participants support the development work. - **Pharmaceutical licensing partners** (primary) — Buy or license development-stage oncology assets such as Cantrixil for further clinical development and commercialization. - **Veterinary oncology partners** (primary) — Potential partners for Paccal Vet who can advance animal cancer programs through later-stage development and market access. - **Clinical research sites** (secondary) — Hospitals and veterinary centers that conduct the company’s pilot, PK, tox, and dose-finding studies. - Pharma/biotech partners seeking licensed oncology assets - Clinical trial sites running human oncology studies - Veterinary clinics and investigators in dog/cat cancer studies - Potential regional partners for development and commercialization ## Geography Vivesto is headquartered in Solna, Sweden and is listed on Nasdaq Stockholm. Its development work is international: the company references activity across the United States, Europe, and Asia, and its Paccal Vet study in dogs is run at multiple clinical centers in the U.S. - **Sweden** (100%) — Headquarters and corporate base; no revenue geography disclosed. - Headquartered in Solna, Sweden - Listed on Nasdaq Stockholm under ticker VIVE - Clinical work spans the United States, Europe, and Asia - Paccal Vet dog study runs at U.S. clinical centers - Global partnering network supports out-licensing efforts ## Strategy Vivesto’s strategy is to advance its two oncology programs through the next value-inflection milestones and use data to support partnering. The company also emphasizes building international business-development relationships so that later-stage development and commercialization can be handled with external partners rather than internally. - **Advance clinical development of Cantrixil** (short-term) — Human oncology data can create partnering interest and future licensing value. - **Progress Paccal Vet studies** (short-term) — Veterinary oncology data can broaden the partner universe and validate the platform. - **Pursue partnering and licensing** (medium-term) — The business model depends on external partners to fund later-stage development and commercialization. - Advance Cantrixil and Paccal Vet toward clinical milestones - Use clinical and preclinical data to attract licensing partners - Leverage both human and veterinary oncology to widen partner pool - Maintain global business-development reach across major life science hubs - Use partnerships for late-stage development and commercialization ## Risks Vivesto is exposed to the typical risks of a development-stage biotech company: clinical failure, regulatory uncertainty, and dependence on external funding and partners. The company also has a concentrated pipeline, so setbacks in either Cantrixil or Paccal Vet could materially affect its value creation path. - **Clinical development failure** [high] — The company’s value depends on positive data from Cantrixil and Paccal Vet studies. - **Financing risk** [high] — As a development-stage biotech with no product revenue, Vivesto depends on capital to fund operations. - **Partnering/commercialization risk** [medium] — The business model assumes later-stage development and commercialization will be done with partners. - **Regulatory and study-design risk** [medium] — Clinical and veterinary studies must satisfy regulators and generate usable data. - Clinical trial outcomes may not confirm safety or efficacy - Funding needs are ongoing until partnering or approvals occur - Partnering risk if licensing discussions do not convert to deals - Concentrated pipeline increases dependence on a few assets - Biotech development timelines are long and uncertain ## Accounting Vivesto reports as a development-stage company with no product revenue, so operating results are driven mainly by research and development spending and financing items. Investors should watch judgment areas such as lease accounting under RFR 2 versus IFRS, the treatment of capital raises and related-party loans, and the evaluation of new standards such as IFRS 18. - **Lease accounting under RFR 2** — Affects balance sheet and expense timing - **Related-party loan conversion and equity issuance** — Affects financing cash flow, equity, and interest expense - **Development-stage expense recognition** — Drives reported operating loss and quarterly volatility - **IFRS 18 transition assessment** — May change line-item presentation and comparability - No product revenue; results mainly reflect R&D and financing costs - Lease accounting differs under RFR 2 versus full IFRS reporting - Related-party loans and conversion terms affect financing presentation - IFRS 18 adoption requires assessment but no value change expected - Single operating segment limits segment disclosure --- *Last updated: 2026-08-11T04:04:56.948908+00:00*